Skip to main content
. 2022 Feb 10;107(9):2064–2071. doi: 10.3324/haematol.2021.280433

Figure 3.

Figure 3.

Overall survival of relapsed/refractory patients with B-acute lymphoblastic leukemia and extramedullary disease afer treatment with Inotuzumab ozogamicin. Green and red dotted lines indicate upper and lower bounds of the 95% confidence interval.